Thomas Gribbin, MD
Hematology & Oncology · Grand Rapids, MINPI 1639179286
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,877, 7.2 times the $261 reported in 2019.
Across 121 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$341
- Merck$326
- Novartis$323
- GSK$239
- Foundation Medicine, Inc.$149
- Gilead$136
- plus $1K from 25 others
Across 3 payments — averaging $400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Array Biopharma Inc$1K
What the payments were for
- Food & beverage$2,56294%
- Education$1776%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $341 |
| Merck | 12 | $326 |
| Novartis | 16 | $323 |
| GSK | 14 | $239 |
| Foundation Medicine, Inc. | 2 | $149 |
| Gilead | 8 | $136 |
| Pfizer | 13 | $134 |
| Geron Corporation | 4 | $111 |
| Genentech USA, Inc. | 3 | $78 |
| Sanofi | 4 | $76 |
| Beone Medicines USA, Inc. | 3 | $75 |
| Regeneron Healthcare Solutions, Inc. | 2 | $75 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $67 |
| AbbVie | 3 | $61 |
| Amneal Pharmaceuticals LLC | 2 | $57 |
| Array Biopharma Inc | 3 | $56 |
| Ipsen Biopharmaceuticals, Inc | 2 | $54 |
| Caris MPI, Inc. | 1 | $52 |
| Daiichi Sankyo Inc. | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Incyte Corporation | 1 | $28 |
| Sobi, Inc | 1 | $25 |
| Agios Pharmaceuticals, Inc. | 1 | $23 |
| Stemline Therapeutics Inc. | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $20 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,739 in reported general payments places this provider in the 60th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 85 | $1,152,973 |
| CerdelgaEliglustat Tartrate | 12 | $388,506 |
| IbrancePalbociclib | 22 | $345,359 |
| PomalystPomalidomide | 15 | $324,650 |
| JakafiRuxolitinib Phosphate | 13 | $227,032 |
| NyvepriaPegfilgrastim-Apgf | 32 | $116,759 |
| NeulastaPegfilgrastim | 17 | $105,627 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $31,680 |
| Exemestane | 61 | $19,168 |
| EliquisApixaban | 30 | $18,709 |
| Anastrozole | 336 | $12,785 |
| Tamoxifen Citrate | 295 | $11,487 |
| Anagrelide Hcl | 20 | $7,075 |
| Letrozole | 60 | $2,979 |
| Acyclovir | 188 | $2,752 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $341 | $1,152,97385 claims |
| PfizerIbrance, Nyvepria, Eliquis | $134 | $480,82784 claims |
| SanofiCerdelga | $76 | $388,50612 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $39 | $324,65015 claims |
| Incyte CorporationJakafi | $28 | $227,03213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $57 | $12715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$305K
- Nehal LakhaniGrand Rapids$13K
- Eric SantosGrand Rapids$11K
- Erin PettijohnGrand Rapids$10K
- Colin HardinGrand Rapids$10K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.